1
项与 scAAV1.tMCK.NTF3(Nationwide Children's Hospital) 相关的临床试验Phase I/IIa Trial Evaluating scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A)
This clinical trial is an open-label one-time injection dose study in which scAAV1.tMCK.NTF3 will be administered by intramuscular injections into muscles in both legs in CMT1A subjects with PMP22 gene duplication. Three subjects ages 18 to 35 years receiving (8.87e11 vg/kg) will be enrolled.
100 项与 scAAV1.tMCK.NTF3(Nationwide Children's Hospital) 相关的临床结果
100 项与 scAAV1.tMCK.NTF3(Nationwide Children's Hospital) 相关的转化医学
100 项与 scAAV1.tMCK.NTF3(Nationwide Children's Hospital) 相关的专利(医药)
100 项与 scAAV1.tMCK.NTF3(Nationwide Children's Hospital) 相关的药物交易